ATF3: Friend or foe in cellular stress and repair? A context-dependent stress rheostat framework.

Abstract

Activating transcription factor 3 (ATF3) is an immediate-early basic leucine zipper transcription factor induced by diverse forms of cellular stress. Although ATF3 is often described as a "double-edged sword," that formulation alone does not explain why the same stress-responsive factor can accompany successful adaptation, regeneration, inflammation resolution, cell death, fibrosis, or tumor progression. Here, we synthesize evidence across neuronal injury, innate immunity, cardiovascular and metabolic stress, cancer, and fibrotic disease and propose that ATF3 is better understood as a context-dependent stress rheostat. We organize ATF3 biology around two complementary principles: a temporal/intensity threshold model, in which the duration and magnitude of the stress response influence whether ATF3 is embedded in adaptive or unresolved pathological programs, and a partner/context-switch model, in which transcriptional output is redirected by cell identity, interacting transcription factors, chromatin state, and the surrounding signaling environment. This framework resolves several apparent contradictions in literature. Transient ATF3 induction can enhance neuronal growth competence, restrain Toll-like receptor (TLR) signaling, and support tissue adaptation, whereas sustained or disease-specific ATF3 programs can contribute to metabolic dysfunction, fibrotic remodeling, or tumor invasion. Importantly, ATF3 expression should not be equated with ATF3 causality: in several settings it marks a stressed cell state while cell fate is determined by additional signaling nodes. We therefore critically evaluate translation. ATF3 is well established as an experimental marker of neuronal and tissue stress, but its broad inducibility, intracellular localization, temporal variability, and cell-state dependence limit its current value as a stand-alone clinical biomarker. Similarly, global activation or inhibition is unlikely to be a generally safe therapeutic strategy. Future development should prioritize cell-resolved ATF3 activity signatures, temporal pharmacodynamic measurements, and context-selective interventions that target the specific ATF3-centered network operating in a defined disease state.